CTOs on the Move

TCR2

www.tcr2.com

 
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.tcr2.com
  • 100 Binney Street Suite 710
    Cambridge, MA USA 02142
  • Phone: 617.949.5200

Executives

Name Title Contact Details
Peter Olagunju
 Chief Technology Officer Profile
Aaron Vernon
 Vice President of Technical Operations Profile

Funding

TCR2 raised $125M on 03/21/2018

Similar Companies

IMMY

Manufacturer of diagnostics for global fungal diseases such as, cryptococcosis, aspergillosis, histoplasmosis, coccidioidomycosis (Valley Fever), blastomycosis, and candida.

AlloVir

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

AAI Pharmaceutical

AAI Pharmaceutical is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DEKA BioSciences

Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.

ZymoGenetics

ZymoGenetics is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.